

## Schering Aktiengesellschaft

[View the current Schering Aktiengesellschaft Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/30288-Schering+Aktiengesellschaft.html)

(<http://www.bioportfolio.com/biorporate/30288-Schering+Aktiengesellschaft.html>)

### Contact Details:

**Müllerstr. 178  
Berlin**

Tel: 49 30 468 11 11  
Fax: 49 30 468 15 305  
Email:

**13353  
Germany**

As a successful pharmaceutical company, we are investing in the future of medicine. We develop drugs of high medical value so as to continuously improve the quality of life.

We make the most of knowledge. Using interdisciplinary networks we build bridges to academic researchers around the world, as well as to highly specialized biotech pioneers and partners in the pharmaceutical industry. We combine our own longstanding medical and pharmaceutical expertise with the latest discoveries from genomic research. Throughout, our research focuses on a meaningful combination of early diagnosis, prevention, treatment and therapy control.

We focus on our chosen fields of expertise:

Gynecology & Andrology

Oncology

Diagnostic Imaging

Specialized Therapeutics

As a global player with over 140 subsidiaries we are in close contact with our customers around the world.

### Press Releases on Schering Aktiengesellschaft:

[Reportlinker Adds](#)

[Intranasal Drug Delivery -](#)

25th November,

Reportlinker

[US Market Trends &](#)

2009

[Analysis](#)

*NEW YORK, Nov. 25 /PRNewswire/  
-- Reportlinker.com announces that  
a new market research report is  
available in its catalogue: Intranasal  
Drug Delivery - US Market Trends &  
Analysis <http://www>*

[Reportlinker Adds  
Veterinary Vaccines - A  
World Market Analysis](#)

25th November,  
2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/  
-- Reportlinker.com announces that  
a new market research report is  
available in its catalogue: *Veterinary  
Vaccines - A World Market Analysis*  
<http://www.reportlinker.com>

[NeurogesX Appoints  
Seasoned Sales and  
Marketing Executive as  
New Board Director](#)

24th November,  
2009

NeurogesX, Inc.

SAN MATEO, Calif., Nov. 24  
/PRNewswire-FirstCall/ --  
NeurogesX, Inc. (Nasdaq: NGSX), a  
biopharmaceutical company  
focused on developing and  
commercializing novel pain  
management therapies, today

[Reportlinker Adds  
Oncology Roadmap: Brand  
Spending Benchmarks and  
Market Forecast to 2013](#)

20th November,  
2009

Reportlinker

NEW YORK, Nov. 20  
/PRNewswire/ -- Reportlinker.com  
announces that a new market  
research report is available in its  
catalogue. *Oncology Roadmap:  
Brand Spending Benchmarks and  
Market Forecast to 2013*

[Reportlinker Adds Imaging  
Agents - A Worldwide  
Market Review](#)

20th November,  
2009

Reportlinker

NEW YORK, Nov. 20  
/PRNewswire/ -- Reportlinker.com  
announces that a new market  
research report is available in its  
catalogue. *Imaging Agents - A  
Worldwide Market Review*  
<http://www.reportlinker.com>

## Schering Aktiengesellschaft Patents:



- 6878720- [VEGF receptor tyrosine kinase inhibitors](#)
- 7053112- [Imidazolidinedione analogs useful as anticoagulants and antithrombotics](#)
- 7056923- [Platelet adenosine diphosphate receptor antagonists](#)
- 7067667- [Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors](#)
- 7084142- [Platelet adenosine diphosphate receptor antagonists](#)
- 7101880- [Peptidic compounds as cysteine protease inhibitors](#)
- 7105563- [Indolinone derivatives and their use in treating disease-states such as cancer](#)
- 7115645- [1,2 diarylbenzimidazoles and their pharmaceutical use](#)
- 7119082- [11.beta.-long-chain-substituted 19-nor-17.alpha.-pregna-1,3,5\(10\)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring](#)
- 7129254- [Effector conjugates, process for their production and their pharmaceutical use](#)
- 7033841- [Process and compounds for use in detecting analytes by measurement of residual magnetism, and the use of the said compounds](#)

- 7026323- [Platelet adenosine diphosphate receptor antagonists](#)
- 7002022- [N-Aryl \(thio\) anthranilic acid amide derivatives, their preparation and their use as VEGF](#)
- 6894038- [Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases](#)
- 6956031- [11.beta.-Substituted 19-nor-17-.alpha.-pregna-1,3,5\(10\)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring](#)
- 6962932- [1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives](#)
- 6966894- [Syringes and injectors incorporating mechanical fluid agitation devices](#)
- 6972290- [Piperazine derivatives and their use as anti-inflammatory agents](#)
- 6977258- [Piperazine derivatives and their use as anti-inflammatory agents](#)
- 6982259- [N-heterocyclic derivatives as NOS inhibitors](#)
- 6987101- [Therapeutic gestagens for the treatment of premenstrual dysphoric disorder](#)
- 6995156- [Platelet adenosine diphosphate receptor antagonists](#)
- 7138379- [Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons](#)
- 7141566- [Benzoxazine and benzothiazine derivatives and the use thereof in medicaments](#)
- 7148207- [Oral fludara of high-purity formulation with quick release of active ingredient](#)
- 7317028- [Cell differentiation inducer](#)
- 7321044- [Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens](#)
- 7329679- [1,2 Diarylbenzimidazoles and their pharmaceutical use](#)
- 7335650- [Composition](#)
- 7335775- [Effector conjugates, process for their production and their pharmaceutical use](#)
- 7345075- [1,2 diarylbenzimidazoles and their pharmaceutical use](#)
- 7378404- [8.beta.-hydrocarbonyl-substituted estratrienes for use as selective estrogens](#)
- 7473415- [Near infrared fluorescent contrast agent and method for fluorescence imaging](#)
- 7504410- [Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents](#)
- 7297702- [Contraception method using competitive progesterone antagonists and novel compounds useful therein](#)
- 7223798- [Lipoxin A.sub.4 analogs](#)
- 7220856- [Substituted quinoline CCR5 receptor antagonists](#)
- 7166592- [Nonsteroidal antiinflammatory agents](#)
- 7176013- [Modified corin molecules having substitute activation sequences and uses thereof](#)
- 7176207- [Platelet adenosine diphosphate receptor antagonists](#)
- 7199146- [Imidazolidinedione analogs useful as anticoagulants and antithrombotics](#)
- 7199268- [Process for the production of dendritic trimesic acid triamides](#)
- 7202263- [N-heterocyclic derivatives as NOS inhibitors](#)
- 7208140- [Trimeric macrocyclic substituted benzene derivatives](#)
- 7211241- [Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes](#)
- 7211680- [Vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments](#)
- 7563924- [9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core

information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

